Novo Nordisk CFO sees oral Wegovy rollout boosting outlook and remains upbeat on CagriSema

Novo Nordisk's chief financial officer, Karsten Munk Knudsen, discussed the company's second‑quarter earnings and the progress of the oral Wegovy pill during a recent interview. He highlighted that the rollout across Europe is proceeding as planned and is a key factor in the company's recent performance.

The CFO explained that Novo Nordisk has raised its full‑year guidance, citing the oral formulation's potential to broaden the obesity market and offset concerns about the broader pipeline. He noted that the pill's convenience could attract new patients and sustain revenue growth.

Despite mixed data from recent CagriSema trials, Knudsen said he remains optimistic about the drug's long‑term prospects. He described the obesity franchise as a "rollercoaster" but emphasized the company's commitment to pursuing growth opportunities in the space.